Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD5672 · 8 trials · 4 indications
The number of participants with greater to or equal to 20% improvement in the ACR composite score (a measure of RA symptoms including: joint swelling and tenderness; patient's assessment of pain, disease activity and physical function; physician's assessment of disease activity; and CRP) after 12 Weeks' treatment.
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | - |
| 2 | EXPERIMENTAL | 20mg |
| 3 | EXPERIMENTAL | 50mg |
| 4 | EXPERIMENTAL | 100mg |
| 5 | EXPERIMENTAL | 150mg |
| 6 | PLACEBO_COMPARATOR | - |
| A | EXPERIMENTAL | 600mg AZD5672 + Moxifloxacin placebo |
| B | EXPERIMENTAL | 100mg AZD5672 + Moxifloxacin placebo |
| C | ACTIVE_COMPARATOR | AZD5672 placebo + Moxifloxacin 400mg |
| D | PLACEBO_COMPARATOR | AZD5672 placebo + Moxifloxacin placebo |
| Name | Type | Description |
|---|---|---|
| AZD5672 | DRUG | 20 mg oral, once daily |
| Etanercept | DRUG | 50 mg, subcutaneous injection, weekly |
| Placebo | DRUG | placebo, oral, once daily |
| Moxifloxacin | DRUG | 1 x 400mg capsule, oral, single dose |
| atorvastatin | DRUG | one single dose of 40 mg on day 10 |
| Digoxin | DRUG | 0.5mg dose |
Inclusion Criteria: * Diagnosis of RA with active disease defined as: ≥4 swollen joints and ≥6 tender/painful joints, and either have (blood tests) elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). * At least one of the following: documented history of positive rheumatoid f...
Top 20 of 28 competitors
AZD5672 is an investigational small molecule being studied for use in renal impairment, rheumatoid arthritis, and healthy volunteers. It has completed four Phase 1 clinical trials with a total enrollment of 465 participants. The drug is not approved and remains in clinical development.
AZD5672 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca has sponsored all four completed Phase 1 clinical trials of AZD5672, which involved healthy volunteers and subjects with renal impairment or rheumatoid arthritis.
AZD5672 is in Phase 1 clinical development. All four trials of AZD5672 are Phase 1 studies and have been completed. The drug is investigational and has not received FDA approval, as it is still in the early stages of clinical testing.
AZD5672 has been studied in four completed Phase 1 trials: NCT00711074, a mass balance and metabolic profiling study in healthy male volunteers; NCT00715702, a safety study in renally impaired subjects; NCT00871767, a bioavailability study; and NCT00887770, a study on cardiac electrical conduction. All trials were controlled, randomized, and double-blind.
AZD5672 is the sole name used for this investigational drug in its clinical trials. No alternative names have been reported for AZD5672 in the completed Phase 1 studies. The drug is a small molecule developed by AstraZeneca for potential use in renal impairment and rheumatoid arthritis.